Uses of bremelanotide in therapy for female sexual dysfunction
Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
1. A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction and anticipating sexual activity, said method comprising administering to the female patient by subcutaneous injection a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide in an amount sufficient to result in a peak plasma concentration of bremelanotide of no more than 120 ng/mL within 60 minutes after administration of the composition, wherein the composition comprises 1.00 mg to 1.75 mg net peptide weight of bremelanotide and comprises 2.5% glycerin (w/v), thereby treating female sexual dysfunction.
2. The method of claim 1 , wherein the peak plasma concentration of bremelanotide is no more than 100 ng/mL within 60 minutes after administration of the composition.
3. The method of claim 1 , wherein the composition comprises 1.75 mg net peptide weight of bremelanotide.
4. The method of claim 1 , wherein the composition is an aqueous solution comprising an acetate salt of bremelanotide.
5. The method of claim 4 , wherein the acetate salt of bremelanotide is between 6% and 12% acetic acid (w/w) in an aqueous solution of bremelanotide.
6. The method of claim 5 , wherein the composition has a pH of 5.0, and wherein the composition further comprises one or more agents to adjust pH.
7. The method of claim 6 , wherein the one or more agents to adjust pH are selected from the group consisting of hydrochloric acid and sodium hydroxide.
8. The method of claim 7 , wherein the composition comprises 1.75 mg net peptide weight of bremelanotide.
9. The method of claim 1 , wherein the female patient is premenopausal.
10. The method of claim 1 , wherein the female patient is postmenopausal.
11. The method of claim 1 , wherein the variability in peak plasma concentration within 60 minutes after subcutaneous administration of the composition is a percent coefficient of variation (% CV) less than 30.
12. The method of claim 1 , wherein the variability in peak plasma concentration within 60 minutes after subcutaneous administration of the composition is less than the variability in peak plasma concentration within 60 minutes after intranasal administration of an equivalent dosage of bremelanotide or a pharmaceutically acceptable salt of bremelanotide.
13. The method of claim 12 , wherein the variability in peak plasma concentration within 60 minutes after intranasal administration is a % CV greater than 30.
14. The method of claim 1 , wherein the female sexual dysfunction is decreased sexual desire.
15. The method of claim 1 , wherein the female sexual dysfunction is hypoactive sexual desire disorder.
16. The method of claim 1 , wherein the female sexual dysfunction is hypoactive sexual desire disorder with female sexual arousal disorder.
17. The method of claim 1 , wherein the female sexual dysfunction is hypoactive sexual desire disorder without female sexual arousal disorder.